Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis
Due to the poor correlation between ROTEM parameters, concizumab exposure, free TFPI and thrombin generation parameters and the lack of consistent and reliable performance of the modified ROTEM assay, it cannot be recommended for general monitoring of patients on concizumab prophylaxis.
Authors
- Cecilia Augustsson (ORCID: https://orcid.org/0000-0001-5587-3712)
- Anne Riddell (ORCID: https://orcid.org/0000-0001-6594-5353)
- N. Butta
- Kasper Halkjær Jensen
- Hermann Eichler
- Pratima Chowdary
- Victor Jiménez‐Yuste
- Andrea Paramo‐Florencio
- Jan Astermark
Institutions
- Department of Health and Social Care (GB)
- Novo Nordisk (Denmark) (DK)
- Hospital Universitario La Paz (ES)
- The Royal Free Hospital (GB)
- London Cancer (GB)
- Hospital La Paz Institute for Health Research (ES)
- Skåne University Hospital (SE)
- CRUK Lung Cancer Centre of Excellence (GB)
- University College London (GB)
- Saarland University (DE)
Publication Details
- Journal
- Haemophilia
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1111/hae.70203
- Primary Topic
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk